All In Biotech

Drug Trial Radar · NCT03911401

Comparison Trial of OPA-15406 Ointment in Pediatric Patients With Atopic Dermatitis

A Multicenter, Randomized, Double-blind, Vehicle Controlled, Parallel-group Comparison Trial to Demonstrate the Superiority of 0.3% and 1% OPA-15406 Ointment to the Vehicle in Pediatric Patients With Atopic Dermatitis (Phase 3 Trial)

Last checked: Nov 19, 2026Latest source record: Jan 25, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 251 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

251

Actual

Start

May 7, 2019

Primary completion

Dec 13, 2019

Study completion Dec 13, 2019

Sponsor

Sponsor type
Industry
First posted
Apr 11, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 2 years, up to 14 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

To demonstrate the superiority of the investigational medicinal product (IMP; 0.3% OPA-15406 ointment, 1% OPA-15406 ointment, or vehicle) to the vehicle when administered twice daily for 4 weeks using success rate in Investigator's Global Assessment (IGA) at Week 4 as the primary endpoint in pediatric patients with Atopic Dermatitis (AD).

Conditions

  • Atopic Dermatitis

Interventions

  • 0.3% OPA-15406Drug

    Twice daily

  • 1% OPA-15406Drug

    Twice daily

  • PlacebosDrug

    Twice daily

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Responder Rate of Investigator's Global Assesment (IGA) of Disease SeverityTime frame: At Week 4

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Kato Dermatology Clinic

    Sapporo, Japan

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.